LG GB125 Guide D'utilisation page 34

Safety Guidelines (Continued)
Three large epidemiology studies have
been published since December
2000. Between them, the studies
investigated any possible association
between the use of wireless phones
and primary brain cancer, glioma,
meningioma, or acoustic neuroma,
tumors of the brain or salivary gland,
leukemia, or other cancers. None of
the studies demonstrated the
existence of any harmful health effects
from wireless phone RF exposures.
However, none of the studies can
answer questions about longterm
exposures, since the average period of
phone use in these studies was
around three years.
5. What research is needed to
decide whether RF exposure from
wireless phones poses a health
risk?
A combination of laboratory studies
and epidemiological studies of people
actually using wireless phones would
provide some of the data that are
needed. Lifetime animal exposure
studies could be completed in a few
years. However, very large numbers of
animals would be needed to provide
reliable proof of a cancer promoting
effect if one exists.
Epidemiological studies can provide
data that is directly applicable to
human populations, but 10 or more
years follow-up may be needed to
provide answers about some health
effects, such as cancer. This is because
the interval between the time of
exposure to a cancer-causing agent
and the time tumors develop - if they
domay be many, many years. The
interpretation of epidemiological
studies is hampered by difficulties in
measuring actual RF exposure during
day-to-day use of wireless phones.
Many factors affect this measurement,
such as the angle at which the phone
is held, or which model of phone is
used.
6. What is the FDA doing to find
out more about the possible
health effects of wireless phone
RF?
The FDA is working with the U.S.
National Toxicology Program and with
groups of investigators around the
world to ensure that high priority
animal studies are conducted to
address important questions about
the effects of exposure to
radiofrequency energy (RF). The FDA
has been a leading participant in the
33